Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) Return on Capital Employed: 2015-2025

Historic Return on Capital Employed for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to 0.19%.

  • CytomX Therapeutics' Return on Capital Employed fell 4.00% to 0.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.19%, marking a year-over-year decrease of 4.00%. This contributed to the annual value of 0.33% for FY2024, which is 42.00% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Return on Capital Employed stood at 0.19%, which was down 58.14% from 0.44% recorded in Q2 2025.
  • CytomX Therapeutics' Return on Capital Employed's 5-year high stood at 0.61% during Q1 2025, with a 5-year trough of -1.11% in Q4 2022.
  • For the 3-year period, CytomX Therapeutics' Return on Capital Employed averaged around 0.07%, with its median value being 0.20% (2024).
  • Per our database at Business Quant, CytomX Therapeutics' Return on Capital Employed plummeted by 73bps in 2022 and then soared by 100bps in 2023.
  • CytomX Therapeutics' Return on Capital Employed (Quarterly) stood at -0.42% in 2021, then slumped by 69bps to -1.11% in 2022, then soared by 100bps to -0.12% in 2023, then surged by 68bps to 0.57% in 2024, then decreased by 4bps to 0.19% in 2025.
  • Its Return on Capital Employed was 0.19% in Q3 2025, compared to 0.44% in Q2 2025 and 0.61% in Q1 2025.